A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Trial Profile

A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Revefenacin (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms COPD
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 25 Jul 2017 Last checked against ClinicalTrials.gov record.
    • 24 May 2017 Results of two identical phase III studies (NCT02459080, NCT02512510) presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results from NCT02459080 and NCT02512510 studies (n=1256) presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top